#WhatsYourTargetScore? We were surprised to see that > $ 50B could have been saved if only the targets that scored a solid 'zero' (or close to zero) were not chased (i.e., #SMAD7, #MadCAM, #TYK2, #CD3e, #CD20, #CTLA4, #TLR9, #IP10, #IL17, #IL36, and the list of 'misses' goes on....in #IBDtherapeutics). That's ok; as they say, hindsight is 20-20. The bigger question is if #FORWARD can generate the kind of foresight from hindsight, that can save at least some of the next $ 50B? #TL1A (Roivant Sciences, Roche, Pfizer and Merck); #PHD1 and #PHD2 (Insilico Medicine); #PDE10 (BenevolentAI); #Ritlecitinib, #Beprocitinib (Pfizer); #PD1-agonist (ONO PHARMA USA); #IBDVentures (Crohn's & Colitis Foundation); others #targetchoice, #targetdiscovery; #efficacy; #IBD; #insilico; #benevolentAI #Ulcerativecolitis; #CrohnsDisease; #IBDVentures; #Pharmaceuticals; #ClinicalOperations; #DrugDiscovery; #inflammatoryboweldisease; #Pharma; #Biotech; #ArtificialIntelligence; #precisionmedicine; #DrugDevelopment; #Biotechnology; #HealthcareInnovation; #DataScience; #AI #precision; #datascience; #machinelearning; #networkmedicine; #drug; #target; #discovery:
The UC San Diego Institute for Network Medicine (iNetMed) was founded with the singular goal of building biological #networks that are #actionable and #disruptive. Thus summer, iNetMed's computational branch, the Center for Precision Computational Systems Network (PreCSN), proudly unveils its first effort in a series aimed at transforming the initial step in #drugdevelopment— #target #choice— through the power of #machinelearning. Despite decades of #explosive growth in #computational #speed and #accuracy, and the era of #generative #AI, skeptics have rightly pointed out [👇#1] that there are no #AI/ #ML solutions to tackle the really #hardstuff: target #choice and #toxicity, two major reasons why #drugdevelopment programs fail. The phase 1/2 success rates of #AI-driven vs non-AI programs remain similar [👇#2] and we may be witnessing overinflated claims of 'new targets' [👇#2] and/or 'new drugs' [👇#3, #4]. Our approach integrates #foundational principles of #math and #biology within a common #framework [👁2-page summary] with the assumption that despite its #complexity, everything in #biology follows some core #fundamental #rules. This mathematical framework exploits rules that govern gene expression to generate a precise #number for #likelihood of #approval index [LoAI]. Over time, the model may very well fall below its current 100% success rate in precision call, but [paraphrasing NASA's #KatherineJohnson] the good thing about #math is that the answer (number) is the same today, as it was yesterday, and will be tomorrow. Link to #1: Derek Lowe: https://lnkd.in/gJRr-4xR Link to #2: Derek Lowe: https://lnkd.in/efddNNFG Link to #3: Derek Lowe: https://lnkd.in/gQt8EjbD Link to #4: Jonathan Hay, summarizes Andreas Bender, Ash Jogalekar and Derek Lowe's take on Insilico Medicine's accomplishments and the evolving landscape of AI-powered drug discovery: https://lnkd.in/gzM2_CP6 Link to PrePRINT: https://lnkd.in/g7S__zPA Shout out to the authors: Saptarshi Sinha, Ella McLaren, Madhubanti Mullick, @Siddharth Singh [https://lnkd.in/gHU6WWJV], Brigid Boland and Pradipta Ghosh. #Gratitude to #Funders: The Helmsley Charitable Trust; National Institute of Allergy and Infectious Diseases (NIAID); National Center for Advancing Translational Sciences (NCATS); American Gastroenterological Association (AGA); Crohn's & Colitis Foundation. #targetchoice, #targetdiscovery; #efficacy; #ClinicalTrials; #IBD; #Ulcerativecolitis; #CrohnsDisease; #IBDVentures; #Pharmaceuticals; #ClinicalOperations; #DrugDiscovery; #inflammatoryboweldisease; #HealthcareInnovation #ClinicalResearch #Pharma; #Biotech #strategy; #ArtificialIntelligence; #precisionmedicine; #BIO2024; #DrugDevelopment; #Biotechnology; #HealthcareInnovation; #DataScience; #AI #precision; #datascience; #machinelearning; #networkmedicine; #News; #drug; #target; #discovery: Turbine.ai; Healx; Insilico Medicine; #NVIDIA.